TRALEMENT
Peaktrace elements injection 4
NDAINTRAVENOUSSOLUTION
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
TRALEMENT (trace elements injection 4) is polymerases, rna polymerases, alcohol dehydrogenase, and alkaline phosphatases. Approved for copper, manganese, selenium for parenteral nutrition and 3 more indications. First approved in 2020.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRALEMENT is an intravenous solution containing trace elements (zinc, copper, manganese, selenium) essential for patients requiring parenteral or enteral nutrition when oral intake is insufficient or contraindicated. The drug functions as a cofactor and catalyst for multiple metalloenzymes involved in protein synthesis, energy metabolism, antioxidant defense, and cellular redox reactions. It restores micronutrient status in critically ill, post-surgical, and nutritionally compromised patients.
Peak15.1 years to LOE
Peak-stage product with stable market position and limited competitive pressure; small, specialized commercial team likely supporting niche hospital/nutritional support channel.
Mechanism of Action
polymerases, RNA polymerases, alcohol dehydrogenase, and alkaline phosphatases. Zinc is a coordinator of protein structural folding that interacts with a variety of proteins, lipids, and nucleic acids. In addition, zinc is a catalyst of essential biochemical reactions, including activation of…
Indications (6)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.